VERAXA Biotech Shareholders Greenlight Merger with Voyager, Authorize Capital Increase
Summary
VERAXA Biotech shareholders have approved the absorption merger into Veraxa Biotech Holding AG and authorized a capital increase of up to CHF 223,400 to issue shares to Voyager Acquisition Corp. This is a significant positive development, as it fulfills a critical condition for the completion of the SPAC merger between Voyager Acquisition Corp. (VACH) and VERAXA Biotech. The approval de-risks the transaction and moves the combined entity closer to its planned listing on Nasdaq under the ticker VRXA. Investors should now monitor for the date of Voyager's shareholder approval and the final closing of the deal.
At the time of this announcement, VACH was trading at $10.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $338.1M. The 52-week trading range was $10.06 to $10.99. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Unknown.